Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Middle East Healthcare Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Middle East Healthcare wird ein jährliches Gewinn- und Umsatzwachstum von 21.8% bzw. 10.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.4% betragen.
Wichtige Informationen
21.8%
Wachstumsrate der Gewinne
23.2%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 15.1% |
| Wachstumsrate der Einnahmen | 10.2% |
| Zukünftige Eigenkapitalrendite | 18.4% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 21 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital
May 30
Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity
Apr 29Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge
Apr 02There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump
Feb 11Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled
Feb 08Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?
Jan 18Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors
Dec 28Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends
Sep 26Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Jun 28Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Mar 30Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal
Sep 20Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)
Jun 14Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture
Apr 18Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Aug 10Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends
Mar 29An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued
Mar 03Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 10Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock
Jan 23If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%
Jan 05Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?
Dec 18Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)
Nov 30Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 3,753 | 415 | 342 | 452 | 5 |
| 12/31/2025 | 3,373 | 349 | 246 | 479 | 6 |
| 12/31/2024 | 3,058 | 251 | 151 | 306 | 4 |
| 3/31/2024 | 2,704 | 182 | 69 | 270 | N/A |
| 12/31/2023 | 2,653 | 180 | -41 | 191 | N/A |
| 9/30/2023 | 2,551 | 177 | 23 | 282 | N/A |
| 6/30/2023 | 2,393 | 135 | 63 | 346 | N/A |
| 3/31/2023 | 2,276 | 105 | -95 | 172 | N/A |
| 12/31/2022 | 2,152 | 75 | -174 | 76 | N/A |
| 9/30/2022 | 2,033 | 24 | -292 | 9 | N/A |
| 6/30/2022 | 2,019 | 27 | -309 | 1 | N/A |
| 3/31/2022 | 1,968 | 26 | -259 | 114 | N/A |
| 12/31/2021 | 1,873 | 17 | -341 | 77 | N/A |
| 9/30/2021 | 1,823 | 45 | -434 | -37 | N/A |
| 6/30/2021 | 1,816 | 66 | -580 | -160 | N/A |
| 3/31/2021 | 1,733 | 73 | -501 | -166 | N/A |
| 12/31/2020 | 1,751 | 82 | -524 | -229 | N/A |
| 9/30/2020 | 1,708 | 110 | -507 | -182 | N/A |
| 6/30/2020 | 1,603 | 108 | -348 | -23 | N/A |
| 3/31/2020 | 1,583 | 104 | -440 | -38 | N/A |
| 12/31/2019 | 1,497 | 98 | -373 | 99 | N/A |
| 9/30/2019 | 1,401 | 91 | -351 | 133 | N/A |
| 6/30/2019 | 1,353 | 78 | -335 | 180 | N/A |
| 3/31/2019 | 1,346 | 100 | -289 | 164 | N/A |
| 12/31/2018 | 1,391 | 172 | -197 | 159 | N/A |
| 9/30/2018 | 1,445 | 224 | -39 | 317 | N/A |
| 6/30/2018 | 1,459 | 269 | -61 | 204 | N/A |
| 3/31/2018 | 1,464 | 297 | -17 | 135 | N/A |
| 12/31/2017 | 1,462 | 319 | N/A | 347 | N/A |
| 9/30/2017 | 1,503 | 322 | N/A | 370 | N/A |
| 6/30/2017 | 1,529 | 356 | N/A | 256 | N/A |
| 3/31/2017 | 1,588 | 368 | N/A | 453 | N/A |
| 12/31/2016 | 1,616 | 363 | N/A | 253 | N/A |
| 9/30/2016 | 1,629 | 380 | N/A | 72 | N/A |
| 6/30/2016 | 1,602 | 371 | N/A | 313 | N/A |
| 3/31/2016 | 1,564 | 389 | N/A | 303 | N/A |
| 12/31/2015 | 1,535 | 390 | N/A | 194 | N/A |
| 9/30/2015 | 1,485 | 373 | N/A | 434 | N/A |
| 6/30/2015 | 1,456 | 356 | N/A | 383 | N/A |
| 3/31/2015 | 1,431 | 357 | N/A | 253 | N/A |
| 12/31/2014 | 1,399 | 332 | N/A | 349 | N/A |
| 12/31/2013 | 828 | 137 | N/A | 129 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 4009Das prognostizierte Gewinnwachstum (21.8% pro Jahr) liegt über der Sparquote (14.3%).
Ertrag vs. Markt: 4009Die Erträge des Unternehmens (21.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (6.8% pro Jahr).
Hohe Wachstumserträge: 4009Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: 4009Die Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (-0.3% pro Jahr).
Hohe Wachstumseinnahmen: 4009Die Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 4009Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.4 %).